Avedro, Inc.
Avedro, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Avedro, Inc..
Avedro, Inc. is a company.
Key people at Avedro, Inc..
Avedro, Inc. is an ophthalmic pharmaceutical and medical device company that develops and commercializes therapies for corneal disorders, glaucoma, and retinal diseases, primarily through cross-linking interventions, drug delivery platforms, and glaucoma management solutions.[1][2][3] It serves the ophthalmology market by addressing corneal ectatic disorders to improve vision and reduce dependency on eyeglasses or contact lenses, with key products like Photrexa® Viscous, Photrexa®, and the KXL® System.[1][2] Founded in 2002 (with some sources noting 2009 activity), the commercial-stage company raised $212.95M before being acquired by Glaukos Corporation in November 2019, integrating into a leader in Micro-Invasive Glaucoma Surgery (MIGS).[1][4]
Avedro originated in 2002 in Waltham, Massachusetts, initially known as ThermalVision, before rebranding to focus on ophthalmic therapies.[1] The company emerged from innovations in corneal cross-linking and related technologies, achieving early milestones such as FDA approval for Photrexa® Viscous, Photrexa®, and the KXL® System in 2016, CFDA approval in China in 2015, and the EU CE Mark for its Vedera™ device in 2010.[2] It pursued an initial public offering (IPO) via SEC S-1 filing in 2019 but was acquired by Glaukos before completion, marking a pivotal shift to operating under a MIGS pioneer.[1][4][5]
Avedro rides the wave of advancing ophthalmic technologies, particularly corneal cross-linking and MIGS, amid rising demand for vision-preserving treatments as populations age and screen time increases corneal issues.[1][4] Its timing aligned with regulatory progress (e.g., 2016 FDA approval) during a boom in minimally invasive eye care, fueled by market forces like expanding glaucoma prevalence and global approvals in China/EU.[2] By integrating into Glaukos, Avedro influences the ecosystem by bolstering cross-linking within MIGS portfolios, accelerating adoption of combined therapies over traditional surgeries and competing with vascular-focused medtech.[1][4]
As a Glaukos subsidiary, Avedro's therapies will likely expand through MIGS synergies, with next steps including broader global rollouts and potential combination devices for glaucoma-corneal care.[1][4] Trends like AI-enhanced diagnostics and personalized ophthalmology will shape its path, amplifying influence in a market projected for sustained growth. This positions Avedro's foundational cross-linking innovations at the heart of transformative eye health solutions, echoing its origins in redefining corneal treatment.
Key people at Avedro, Inc..
